Author:
Watanabe Fumiya,Matsumoto Yasuhiko,Sugita Takashi,Morishige Yuta,Mitarai Satoshi,Hoshino Yoshihiko,Hanada Kazuhiko
Funder
Nagai Memorial Research Scholarship
the Joint Research Program in Meiji Pharmaceutical University
Encouragement of Scientists
Japan Agency for Medical Research and Development/Japan International Cooperation Agency
Scientific Research
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Daley, C. L. et al. Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur. Respir. J. 56, 2000535 (2020).
2. Namkoong, H. et al. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg. Infect. Dis. 22, 1116–1117 (2016).
3. Kwak, N. et al. Treatment outcomes of Mycobacterium avium complex lung disease: A systematic review and meta-analysis. Clin. Infect. Dis. 65, 1077–1084 (2017).
4. Morimoto, K. et al. Macrolide-resistant Mycobacterium avium complex lung disease: Analysis of 102 consecutive cases. Ann. Am. Thorac. Soc. 13, 1904–1911 (2016).
5. Watanabe, F. et al. Low-dosage ethambutol, less than 12.5 mg/kg/day, does not worsen the clinical outcomes of pulmonary Mycobacterium avium and Mycobacterium intracellulare disease: A retrospective cohort study. Infection 50, 879–887 (2022).